In the published article, there was an error. The dataset from GEO database we used for analysis was GSE38958 but written or revised wrongly in section of Abstract and Introduction.
A correction has been made to Abstract, “Paragraph 1.” This sentence previously stated:
“In this study, 12 significant m6A regulators were filtered out between healthy controls and IPF patients using GSE33566 dataset.”
The corrected sentence appears below:
“In this study, 12 significant m6A regulators were filtered out between healthy controls and IPF patients using GSE38958 dataset.”
Another correction has been made to Introduction, “Paragraph 4.” This sentence previously stated:
“In our research, we comprehensively assessed the effects of m6A regulators on the diagnosis and subtype categorization in IPF using the GSE33566 dataset.”
The corrected sentence appears below:
“In our research, we comprehensively assessed the effects of m6A regulators on the diagnosis and subtype categorization in IPF using the GSE38958 dataset.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
idiopathic pulmonary fibrosis, m6A regulators, diagnostic model, consensus clustering, prognostic markers, novel therapeutic targets
Citation
Huang G, Huang S and Cui H (2022) Corrigendum: Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis. Front. Pharmacol. 13:1117317. doi: 10.3389/fphar.2022.1117317
Received
06 December 2022
Accepted
07 December 2022
Published
16 December 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Huang, Huang and Cui.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongsheng Cui, hshcui@sina.com
This article was submitted to Respiratory Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.